article thumbnail

Partnering for success in early phase clinical development

Bio Pharma Dive

Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Marketing 306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

Despite the market size for B-cell non-Hodgkin’s lymphoma (NHL) being at least five times that of ALL, NHL has a smaller pipeline of cell therapies. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Worldwide Clinical Trials

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.

article thumbnail

Centers of excellence or product-centric BizDevOps managed services?

Bio Pharma Dive

As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.

article thumbnail

How Can You Manage the Complexity of Early Phase Clinical Development?

XTalks

Oren Cohen, MD, FIDSA CMO & President of Clinical Pharmacology Fortrea Fortrea is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, market access solutions and other enabling services.

article thumbnail

Why Should Companies Use Digital Endpoints Across Clinical Development?

XTalks

Phase III trials: In these advanced stages, focused on confirming efficacy and monitoring side effects in larger populations, DHTs may support market authorization and label claims. This approach can speed up development and improve data quality, potentially leading to more effective and personalized therapies.